Two Phase III trials of PARP inhibitors in mCRPC

There are now two, ongoing, Phase III trials of PARP inhibitors in the treatment of eligible patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Second PARP inhibitor approved by FDA (but still not for prostate cancer)

A second PARP inhibitor has recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with BRCA1/2 mutations and advanced ovarian cancer who have already received two types of chemotherapy. … READ MORE …

Abiraterone + veliparib in treatment of men with mCRPC

Another important set of data that came out of the ASCO session that your sitemaster was unable to attend were the data presented by Dr. Maha Hussain on the use of the PARP inhibitor veliparib.

J&J investing further in potential drugs for advanced prostate cancer

Johnson & Johnson has just acquired the rights to develop and sell a drug called niraparib for the treatment of prostate cancer everywhere in the world except Japan. The developer, Waltham, MA-based Tesaro, has retained the rights to niraparib in Japan. … READ MORE …

Published data on activity of olaparib in some men with mCRPC

A paper in the New England Journal of Medicine now provides detailed information about the activity of the PARP inhibitor olaparib in the treatment of carefully selected patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Olaparib continues to show promise in very late stage prostate cancer

According to a presentation at the ongoing annual meeting of the American Association for Cancer Research (AACR) meeting here in  Philadelphia, AstraZeneca’s PARP inhibiting agent — olaparib or Lynparza — continues to show promise in very late stage metastatic, castration-resistant prostate cancer. … READ MORE …

Does olaparib have real potential in treatment of mCRPC?

According to a report on the Reuters web site yesterday, some researchers are of the opinion that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (recently recommended for approval in Europe for the treatment of a subset of women with ovarian cancer) may be valuable in the treatment of some forms of prostate cancer too. … READ MORE …